A conjugate of the formula B-L-A, wherein B is an LHRH-R binding antagonist of the formula wherein each R 1 is independently halogen, C 1 -C 6 alkyl or -OC 1 -C 6 alkyl, each R 2 is independently H, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; R 3 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl or C 1 -C 6 alkyl-(C 6 -C 10 aryl); R 4 is C 1 -C 6 alkyl; each R 5 is independently selected from the group consisting of halogen, C 1 -C 6 alkyl, -OC 1 -C 6 alkyl, -SC 1 -C 6 alkyl and -OC 6 -C 10 aryl; X and Y are each independently N, CH or CR 1; provided that when X is N, Y is CH or CR 1, and when Y is N, X is CH or CR 1; m is an integer from 0 to 4; n is an integer from 0 to 3; and * represents a covalent bond to L; L is a linker selected from the group consisting of (a) at least one amino acid, preferably selected from the group consisting of Lys, Asn, Thr, Ser, Ile, Met, Pro, His, Gln, Arg, Gly, Asp, Glu, Ala, Val, Phe, Leu, Tyr, Cys, and Trp; or (b) at least two amino acids independently selected from the group consisting of Glu and Cys; or (c) an amino acid portion of the formula Glu-Glu, wherein the glutamic acids are covalently bonded to each other through the carboxylic acid side chains; or (d) one or more hydrophilic spacer linkers comprising a plurality of hydroxyl functional groups; or (e) a moiety of the formula wherein p is an integer from 3 to 10, q is an integer from 3 to 100; and each * represents a covalent bond to the rest of the conjugate; or (f) a portion selected from the group consisting of and wherein R 6 is H or C 1 -C 6 alkyl; and each * represents a covalent bond to the rest of the conjugate; or (g) wherein the linker comprises a portion selected from the group consisting of wherein each of R 7 and R 8 is independently H or C 1 -C 6 alkyl; t is an integer from 1 to 8; and each * represents a covalent bond to the rest of the conjugate; and (h) combinations thereof; and A is a drug therapeutically effective against cancer cells and/or cancer-associated fibroblast (CAFs) or an imaging agent; or a pharmaceutically acceptable salt thereof. each R 1 is independently halogen, C 1 -C 6 alkyl or -OC 1 -C 6 alkyl, each R 2 is independently H, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; R 3 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl or C 1 -C 6 alkyl-(C 6 -C 10 aryl); R 4 is C 1 -C 6 alkyl; each R 5 is independently selected from the group consisting of halogen, C 1 -C 6 alkyl, -OC 1 -C 6 alkyl, -SC 1 -C 6 alkyl and -OC 6 -C 10 aryl; X and Y are each independently N, CH or CR 1; provided that when X is N, Y is CH or CR 1, and when Y is N, X is CH or CR 1; m is an integer from 0 to 4; n is an integer from 0 to 3; and * represents a covalent bond to L; L is a linker selected from the group consisting of (a) at least one amino acid, preferably selected from the group consisting of Lys, Asn, Thr, Ser, Ile, Met, Pro, His, Gln, Arg, Gly, Asp, Glu, Ala, Val, Phe, Leu, Tyr, Cys, and Trp; or (b) at least two amino acids independently selected from the group consisting of Glu and Cys; or (c) an amino acid portion of the formula Glu-Glu, wherein the glutamic acids are covalently bonded to each other through the carboxylic acid side chains; or (d) one or more hydrophilic spacer linkers comprising a plurality of hydroxyl functional groups; or (e) a moiety of the formula wherein p is an integer from 3 to 10, q is an integer from 3 to 100; and each * represents a covalent bond to the rest of the conjugate; or (f) a portion selected from the group consisting of and wherein R 6 is H or C 1 -C 6 alkyl; and each * represents a covalent bond to the rest of the conjugate; or (g) wherein the linker comprises a portion selected from the group consisting of wherein each of R 7 and R 8 is independently H or C 1 -C 6 alkyl; t is an integer from 1 to 8; and each * represents a covalent bond to the rest of the conjugate; and (h) combinations thereof; and (a) at least one amino acid, preferably selected from the group consisting of Lys, Asn, Thr, Ser, Ile, Met, Pro, His, Gln, Arg, Gly, Asp, Glu, Ala, Val, Phe, Leu, Tyr, Cys, and Trp; or (b) at least two amino acids independently selected from the group consisting of Glu and Cys; or (c) an amino acid portion of the formula Glu-Glu, wherein the glutamic acids are covalently bonded to each other through the carboxylic acid side chains; or (d) one or more hydrophilic spacer linkers comprising a plurality of hydroxyl functional groups; or (e) a moiety of the formula wherein p is an integer from 3 to 10, q is an integer from 3 to 100; and each * represents a covalent bond to the rest of the conjugate; or (f) a portion selected from the group consisting of and wherein R 6 is H or C 1 -C 6 alkyl; and each * represents a covalent bond to the rest of the conjugate; or wherein R 6 is H or C 1 -C 6 alkyl; and each * represents a covalent bond to the rest of the conjugate; or (g) wherein the linker comprises a portion selected from the group consisting of wherein each of R 7 and R 8 is independently H or C 1 -C 6 alkyl; t is an integer from 1 to 8; and each * represents a covalent bond to the rest of the conjugate; and each of R 7 and R 8 is independently H or C 1 -C 6 alkyl; t is an integer from 1 to 8; and each * represents a covalent bond to the rest of the conjugate; and (h) combinations thereof; and A is a drug therapeutically effective against cancer cells and/or cancer-associated fibroblast (CAFs) or an imaging agent;